CONMED Corporation stated today that it has completed its previously announced acquisition of In2Bones Global Inc, a privately owned company.
In2Bones is a global researcher, manufacturer, and distributor of medical devices for the treatment of illnesses and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities, with headquarters in Memphis, Tennessee. Implants, fracture systems, biologics, and related hardware are among the company’s diverse product offerings.
The transaction is funded with the net proceeds of the Company’s 2.25 percent convertible notes, which were issued on June 6, 2022, as well as borrowings under the Company’s amended and restated credit facility and cash on hand. When the Company releases its second quarter financial results in late July, it will provide additional guidance on the transaction’s impact on 2022 financial performance.
